Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087385 | 0.88 | KDM4E (0.46) | ALDH1A1SMN1; SMN2KDM4ELMNAHTT | |
| SCHEMBL2087893 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4ELMNAHTT | |
| SCHEMBL24003104 | 0.87 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4ELMNAHTT | |
| SCHEMBL25447997 | 0.84 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KDM4ELMNAHTT | |
| SCHEMBL20568495 | 0.84 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2KDM4ELMNAHTT | |
| SCHEMBL24002697 | 0.84 | CNR2 (0.49) | ALDH1A1SMN1; SMN2KDM4ELMNACNR2 | |
| SCHEMBL25446809 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KDM4ELMNACNR2 | |
| SCHEMBL30187192 | 0.83 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KDM4ELMNACNR2 | |
| SCHEMBL24003154 | 0.83 | CNR2 (0.53) | ALDH1A1SMN1; SMN2KDM4ELMNACNR2 | |
| SCHEMBL30187103 | 0.83 | CNR2 (0.53) | ALDH1A1SMN1; SMN2KDM4ELMNACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1991227-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007103905-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | ALDH1A1 319/4885SMN1; SMN2 3690/4885KDM4E 566/4885 |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | ALDH1A1 319/4885SMN1; SMN2 3690/4885KDM4E 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.